Solasia Pharma KK (9SO) Stock Price & Analysis
9SO Stock Chart & Stats
- Day’s Range
- EUR 0.13 - EUR 0.13
- 52-Week Range
- EUR 0.09 - EUR 0.20
- Previous Close
- EUR 0.14
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 41.74M
- Enterprise Value
- EUR 5.89B
- Total Cash (Recent Filing)
- EUR 1.29B
- Total Debt (Recent Filing)
- EUR 78.00M
- Price to Earnings (P/E)
- ―
- Beta
- 0.88
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Partnered Oncology Business Model
Its oncology and supportive-care focus, combined with licensing and collaboration economics, ties revenue opportunities to development milestones, approvals, partner commercialization and royalties. This model can extend market reach while relying on partners for commercialization in relevant territories.
Low Financial Leverage
Very low debt relative to equity limits near-term interest and refinancing pressure, giving the company more balance-sheet flexibility than a highly leveraged peer. This provides some capacity to manage ongoing development needs even though operating performance remains weak.
Improved Gross Margin
The return to positive gross margin indicates that product-related economics have improved from 2024 and creates a better foundation for future operating leverage. If maintained as revenue develops, this improvement could help narrow losses and support more efficient commercialization.
Bears Say
Persistent Cash Burn
Sustained negative operating and free cash flow means the business is not currently funding itself through operations. Continued cash consumption can increase dependence on external financing, constrain investment choices, and create dilution or funding pressure if the pattern persists.
Deep And Persistent Losses
Large recurring losses show that the current cost base remains far above the revenue generated by the business. Without clear evidence of operating leverage or breakeven, profitability remains a fundamental weakness that can limit reinvestment and weaken financial resilience.
Revenue Volatility And Equity Erosion
Recent revenue contraction combined with declining equity indicates that the company has not yet established a stable growth trajectory or protected its capital base. Continued losses could further reduce shareholder equity, leaving less capacity to absorb setbacks or finance development.
Solasia Pharma KK News
9SO FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
What is Solasia Pharma KK’s market cap?
When is Solasia Pharma KK’s upcoming earnings report date?
How were Solasia Pharma KK’s earnings last quarter?
Is Solasia Pharma KK overvalued?
Does Solasia Pharma KK pay dividends?
What is Solasia Pharma KK’s EPS estimate?
How many shares outstanding does Solasia Pharma KK have?
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Solasia Pharma KK?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Solasia Pharma KK
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yoshihiro Arai
- Employees
- 22
- Website
- www.solasia.co.jp
- Address
- Sumitomo Fudosan Shiba-Koen Tower, Tokyo, TY, 105-0011, JP
Solasia Pharma KK (9SO) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |